Insider trade

Prelude Therapeutics (PRLD): CEO bought ~$6.1K

Krishna Vaddi, CEO at Prelude Therapeutics, bought ~$6.1K of Prelude Therapeutics shares.

~$6.1K
Approx. value · 6,888 sh @ $0.8879
128K
Holds after · shares reported
Traded
Dec 19, 2024
Filed
Dec 20, 2024

What stands out in this filing

  • The purchase added 5.7% to the shares this insider held before it; the filing reports 127,553 shares, held indirectly afterwards.
  • 6,888 shares at an average of $0.8879 each, as reported on the form.
  • The first open-market purchase by this insider in 0 months.
  • 2 other insiders at PRLD also bought in the open market within 30 days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 18, 2024InsiderCEO purchased ~$93K of PRLD shares in the open market
  2. Dec 19, 2024 · this disclosureInsiderCEO purchased ~$6.1K of PRLD shares in the open market

What came next

  1. Dec 19, 2024InsiderCFO purchased ~$23K of PRLD shares in the open market
  2. Dec 23, 2024InsiderOfficer purchased ~$82K of PRLD shares in the open market
  3. Dec 30, 2024InsiderCEO purchased ~$12K of PRLD shares in the open market
  4. Dec 31, 2024InsiderCEO purchased ~$6K of PRLD shares in the open market
  5. Mar 12, 2025InsiderCEO purchased ~$34K of PRLD shares in the open market
  6. Mar 13, 2025InsiderCEO purchased ~$36K of PRLD shares in the open market
  7. Mar 14, 2025InsiderCEO purchased ~$23K of PRLD shares in the open market
  8. Mar 17, 2025InsiderCEO purchased ~$6.8K of PRLD shares in the open market
  9. Mar 20, 2025InsiderCEO purchased ~$4K of PRLD shares in the open market
  10. Mar 21, 2025InsiderCEO purchased ~$11K of PRLD shares in the open market
  11. Mar 25, 2025InsiderCEO purchased ~$467K of PRLD shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Prelude Therapeutics

OQRO holds no insider, Congress, fund or contract record for Prelude Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PRLD page.

Other recent filings by Krishna Vaddi, CEO

The full history of Krishna Vaddi, CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Prelude Therapeutics (PRLD) insider traded, and how much?

Krishna Vaddi, CEO at Prelude Therapeutics, bought ~$6.1K of Prelude Therapeutics shares. 6,888 shares at $0.89, open market.

When did it happen, and when was it made public?

Traded: Dec 19, 2024. Filed: Dec 20, 2024. That is 1 day between the two dates.

What stands out in this filing?

The purchase added 5.7% to the shares this insider held before it; the filing reports 127,553 shares, held indirectly afterwards. 6,888 shares at an average of $0.8879 each, as reported on the form. The first open-market purchase by this insider in 0 months.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean PRLD stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Prelude Therapeutics

Everything OQRO holds on this company is on its PRLD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data